These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27633846)

  • 1. Neuroproteomic tools for battling Alzheimer's disease.
    Veenstra TD
    Proteomics; 2016 Nov; 16(22):2847-2853. PubMed ID: 27633846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using stable isotope labeling to advance our understanding of Alzheimer's disease etiology and pathology.
    Hark TJ; Savas JN
    J Neurochem; 2021 Oct; 159(2):318-329. PubMed ID: 33434345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids.
    Galozzi S; Marcus K; Barkovits K
    Expert Rev Proteomics; 2015 Aug; 12(4):343-54. PubMed ID: 26153725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of mass spectrometry to study amyloid-β peptides.
    Grasso G
    Mass Spectrom Rev; 2011; 30(3):347-65. PubMed ID: 21500241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications.
    Bros P; Delatour V; Vialaret J; Lalere B; Barthelemy N; Gabelle A; Lehmann S; Hirtz C
    Clin Chem Lab Med; 2015 Sep; 53(10):1483-93. PubMed ID: 25719328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond.
    Grasso G
    Mass Spectrom Rev; 2019 Jan; 38(1):34-48. PubMed ID: 29905953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.
    Robinson RA; Amin B; Guest PC
    Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential therapeutic agents against Alzheimer's disease from natural sources.
    Park SY
    Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation proteomics technologies in Alzheimer's disease: from clinical research to routine diagnostics.
    Weiner S; Blennow K; Zetterberg H; Gobom J
    Expert Rev Proteomics; 2023; 20(7-9):143-150. PubMed ID: 37701966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development.
    Ising C; Stanley M; Holtzman DM
    Clin Pharmacol Ther; 2015 Nov; 98(5):469-71. PubMed ID: 26250900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.
    Cilento EM; Jin L; Stewart T; Shi M; Sheng L; Zhang J
    J Neurochem; 2019 Nov; 151(4):397-416. PubMed ID: 30474862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease 2012: the great amyloid gamble.
    Marchesi VT
    Am J Pathol; 2012 May; 180(5):1762-7. PubMed ID: 22472273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metals, membranes, and amyloid-β oligomers: key pieces in the Alzheimer's disease puzzle?
    Watt AD; Villemagne VL; Barnham KJ
    J Alzheimers Dis; 2013; 33 Suppl 1():S283-93. PubMed ID: 22699851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
    Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
    Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving Relevance of Neuroproteomics in Alzheimer's Disease.
    Lista S; Zetterberg H; O'Bryant SE; Blennow K; Hampel H
    Methods Mol Biol; 2017; 1598():101-115. PubMed ID: 28508359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Explorative and targeted neuroproteomics in Alzheimer's disease.
    Brinkmalm A; Portelius E; Öhrfelt A; Brinkmalm G; Andreasson U; Gobom J; Blennow K; Zetterberg H
    Biochim Biophys Acta; 2015 Jul; 1854(7):769-78. PubMed ID: 25619854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis and treatment of dementia: overview].
    Furukawa K; Ishiki A; Tomita N; Arai H
    Rinsho Shinkeigaku; 2014; 54(12):1171-3. PubMed ID: 25672736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a sensitive mouse Aβ40 PD biomarker assay for Alzheimer's disease drug development in wild-type mice.
    Lu Y; Hoyte K; Montgomery WH; Luk W; He D; Meilandt WJ; Zuchero YJ; Atwal JK; Scearce-Levie K; Watts RJ; DeForge LE
    Bioanalysis; 2016 May; 8(10):1067-75. PubMed ID: 27094761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tools of the trade: investigations into design strategies of small molecules to target components in Alzheimer's disease.
    Derrick JS; Lim MH
    Chembiochem; 2015 Apr; 16(6):887-98. PubMed ID: 25773481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.